Human HLA-B27 nucleic acid detection kit (fluorescence PCR method)

Human Leukocyte Antigen B27(HLA-B27) Polymerase Chain Reaction(PCR) Fluorescence Detection Kit

The human leukocyte antigen-B27 (HLA-B27) gene is an allele at the B site of the major histocompatibility complex (MHC) class I molecule in humans. It is expressed in almost all nucleated cells of the human body, particularly on the surface of lymphocytes.

Research has shown that ankylosing spondylitis (AS) is a chronic autoimmune disease associated with the HLA-B27 gene and is related to genetic factors. According to statistics, there are over 4 million AS patients in China, and more than 90% of AS patients have positive HLA-B27 antigen expression, while only 5-10% of the general population are positive. The most significant changes in this disease are joint fibrosis and skeletal rigidity. If not treated in a timely manner, it can easily lead to joint deformities and lifelong pain for patients, hence it is known as the 'cancer that never dies'. In addition, AS has similar symptoms to many diseases and is difficult to diagnose, so the detection of HLA-B27 has important clinical significance for the early diagnosis, timely treatment, and active prevention of AS.

The HLA-B27 nucleic acid detection kit (fluorescence PCR method) developed by our company can detect subtypes of B2702, B2704, and B2705 genes related to AS, and can identify susceptible populations for AS in a random population; For individuals with a family history of ankylosing spondylitis, HLA-B27 testing can serve as one of the indicators for early warning and diagnosis of ankylosing spondylitis; For patients with ankylosing spondylitis with clear clinical indications, HLA-B27 testing can serve as an important auxiliary tool for clinical diagnosis and differential diagnosis.

Anti interference ability: Common PCR inhibitors in the sample, such as blood lipids, hemoglobin, drugs, etc., have no effect on the detection results, improving the reliability of the detection

At present, clinical laboratories use flow cytometry technology to detect the expression antigen of HLA-B27 gene, which greatly improves the sensitivity and specificity of detection and shortens the detection time. However, due to the expensive equipment, high requirements for operators and the quality of the samples to be tested, the promotion and application of this technology are limited to a certain extent. The fluorescence PCR method has advantages such as strong specificity, high sensitivity, and speed. This provides the possibility to improve the accuracy and precision of HLA-B27 detection.

The internal reference designed in this kit also participates in sample extraction, enabling monitoring of the detection process in a fully enclosed reaction system, effectively preventing false negatives, and ensuring the accuracy and reliability of the detection results. The sample pre-processing is combined with an automated nucleic acid extraction instrument and supporting extraction reagents, which is easy and fast to operate, and can effectively reduce errors caused by manual operation.

clinical application

1. HLA-B27 testing can assist in the diagnosis of AS. The positivity rate of HLA-B27 in AS patients is greater than 90%. Early diagnosis can provide clues for the diagnosis and differential diagnosis of such patients, making up for the deficiency of X-rays in early diagnosis of AS. HLA-B27 detection has become an important tool for clinical auxiliary diagnosis and early risk assessment of AS.

2. HLA-B27 testing can predict the outcome of pediatric idiopathic arthritis and has certain significance for the prevention of AS.

3. HLA-B27, as an MHC class I molecule, not only plays an important role in antiviral and anti-tumor activities, but also has certain value in clinical research.